KDNY — Chinook Therapeutics Share News
0.000.00%
Last trade - 00:00- $2.90bn
- $2.60bn
- $6.13m
Chinook shares down about 6%, paring steep loss after Muddy Waters reveals short position in drugmaker (updated)
U.S. STOCKS ON THE MOVE-Shake Shack, Western Alliance, Blue Apron
Chinook falls after Muddy Waters' short position, Ionis collab
Chinook Therapeutics falls on collaboration deal with Ionis for kidney therapy
Muddy Waters takes short position in drugmaker Chinook - report
Brief: Chinook Therapeutics Announces Partnership With Ionis To Develop Antisense Therapy For Rare, Severe Chronic Kidney Disease
Chinook Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Chinook Therapeutics Reports First Quarter 2023 Financial Results
Chinook Therapeutics Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Chinook Therapeutics Announces The Appointment Of Robert W. Azelby To Its Board Of Directors
U.S. STOCKS ON THE MOVE-Boeing, Carrier Global, Copper miners
U.S. STOCKS ON THE MOVE-Adaptimmune, Blink Charging, Silver miners
U.S. STOCKS ON THE MOVE-Regenxbio, Pear Therapeutics, Getty Images
Chinook Therapeutics slips on pausing patient dosing in kidney disorder drug trial
Brief: Chinook Therapeutics Pauses Dosing Of Chk-336 In Ongoing Phase 1 Trial
Brief: Chinook Therapeutics Holds Immaterial Amount Of Cash And Cash Equivalents With Svb
Brief: Chinook Therapeutics Reports Q4 And FY 2022 Financial Results And Provides Corporate Updates
Brief: Chinook Therapeutics Reports Q4 Loss Per Share $0.9
Brief: Chinook Therapeutics Announces The Appointment Of Andrew Oxtoby As Chief Commercial Officer